Since 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) have been shown to ameliorate the signs of experimental preeclampsia via upregulation of PlGF expression (Kumasawa et al., 2011), their efficacy and safety for prevention of preeclampsia are currently being tested in two clinical trials (Ahmed, 2011; Costantine and Cleary, 2013). Here, PGF is linked to preeclampsia.